You don't need it to sell supplements. The case for HealthInsu™ is differentiation: in markets crowded with brand- and channel-driven competition, a verifiable, insurance-linked structure changes the conversation from "trust our marketing" to "here is a transparent 1-year structure." It is most useful for higher-ticket, subscription, or trust-deficit categories.

That is exactly what the pilot is designed to measure. We start with one product, one cohort (100 → 300 → 1,000) over a 12-month window, and track purchase conversion, 12-month retention, repurchase rate, and compensation-claim rate. Pilot results then inform whether — and how — to scale.

The compensation structure is co-defined per licensee, against local insurance partners. Typically the licensee operates the consumer-facing program, while an insurance partner underwrites the actual benefit. The exact split (and the role of marketing budget, sub-licensing fees, and trial-program revenue) is part of the 90-day feasibility and the master license terms.

This is the single most important regulatory question, and it is handled at three layers: (1) approved language standards that avoid disease-prevention claims; (2) local legal review during 90-day feasibility; (3) operational training for sales and customer service. HealthInsu™ positions the offering as prevention category with verified usage and conditional benefit, not as medical efficacy.

Then we localize the structure or, in some cases, decline the market. The 90-day feasibility window exists precisely to surface regulatory friction before either side commits. Most markets we have reviewed can adopt HealthInsu™ with adjustments; a few cannot, and that is identified during scan, not after signing.

No. The sequence is NDA → 90-day feasibility → country term sheet → 100-person pilot → 12-month observation → master license. Real money commitments happen at term sheet and pilot stages, not at NDA.

Structure briefing (days 1–14), local regulatory and insurance scan (15–45), partner shortlist of 2–3 insurers, 2–3 manufacturers, and 1+ clinical partner per vertical (46–75), and a country term sheet (76–90). It is a joint exercise — both sides qualify the market together.

The model fits country-level operators who can credibly assemble three local relationships: an insurance partner, a supplement manufacturer (or import partner), and a marketing or distribution channel. Holding companies, healthcare investors, integrated clinics, and well-networked entrepreneurs all qualify. Solo founders without partner access typically do not.

The license includes Jowin's HealthInsu™ business-model patents and system patents covering the prevention-subscription-to-insurance-benefit linkage, plus disease-specific preventive formulas and ingredient supply. The full IP scope (filing numbers, jurisdictions, remaining term, exact claim coverage) is disclosed under NDA during 90-day feasibility.

The pilot exists to find that out cheaply. If retention and repurchase metrics fall below thresholds, we adjust the product mix, communication, or benefit structure — and re-pilot. If the country simply does not respond, both sides exit before a full master license. That optionality is the point of starting at 100 people, not 100,000.

Yes — that is one of the five revenue layers. The master license includes vertical sub-licensing rights so you can grant disease-specific licenses (eyecare, dental, joint, women's health, oncology) to local specialty operators, under your country-level exclusivity.

A typical partnership pairs an existing product with an existing insurance policy. HealthInsu™ is a structural license — it gives you a tested model (subscription, validation, benefit, data) plus the right to localize it. You are not licensing a product; you are licensing a market structure.